10-May-2024
Profound Medical Forecasts Robust Growth in 2024
TipRanks (Thu, 9-May 5:28 PM ET)
Profound Medical GAAP EPS of $0.26 beats by $0.57, revenue of $1.91M misses by $0.59M
Seeking Alpha News (Thu, 9-May 5:24 PM ET)
Profound Medical Predicts Stronger TULSA Adoption
TipRanks (Thu, 9-May 4:50 PM ET)
Globe Newswire (Thu, 9-May 4:05 PM ET)
Globe Newswire (Mon, 6-May 4:15 PM ET)
Profound Medical to Release First Quarter 2024 Financial Results on May 9 Conference Call to Follow
Globe Newswire (Mon, 22-Apr 4:15 PM ET)
Profound Medical to Participate in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Globe Newswire (Tue, 9-Apr 7:45 AM ET)
Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results
Globe Newswire (Thu, 7-Mar 4:05 PM ET)
Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference
Globe Newswire (Mon, 4-Mar 4:30 PM ET)
Globe Newswire (Tue, 27-Feb 7:45 AM ET)
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of customizable, incision-free therapeutic systems for the image-guided ablation of diseased tissue utilizing its platform technologies and leveraging the healthcare system's existing imaging infrastructure. The company's product TULSA-PRO system combines real-time MRI, robotically driven transurethral sweeping-action thermal ultrasound with closed-loop temperature feedback control for the ablation of prostate tissue. The product is comprised of one-time-use devices and durable equipment that are used in conjunction with a customer's existing MRI scanner.
Profound Medical Corp. trades on the NASDAQ stock market under the symbol PROF.
As of May 10, 2024, PROF stock price declined to $7.73 with 80,492 million shares trading.
PROF has a beta of 1.44, meaning it tends to be more sensitive to market movements. PROF has a correlation of 0.07 to the broad based SPY ETF.
PROF has a market cap of $188.80 million. This is considered a Micro Cap stock.
Last quarter Profound Medical Corp. reported $2 million in Revenue and -$.26 earnings per share. This fell short of revenue expectation by $-610,000 and exceeded earnings estimates by $.04.
In the last 3 years, PROF stock traded as high as $19.32 and as low as $3.10.
The top ETF exchange traded funds that PROF belongs to (by Net Assets): DFIS, DFIC.
PROF has underperformed the market in the last year with a price return of -41.7% while the SPY ETF gained +27.8%. PROF has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -11.6% and -3.7%, respectively, while the SPY returned +4.2% and +2.5%, respectively.
PROF support price is $8.13 and resistance is $8.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PROF stock will trade within this expected range on the day.